NLRP3 inflammasome activation involved in LPS and coal tar pitch extract-induced malignant transformation of human bronchial epithelial cells.
Animals
Cell Line
Cell Transformation, Neoplastic
/ drug effects
Coal Tar
/ toxicity
Epithelial Cells
/ drug effects
Humans
Inflammasomes
/ immunology
Inflammation
Interleukin-1beta
/ metabolism
Lipopolysaccharides
/ toxicity
Lung Neoplasms
/ chemically induced
Mice, Inbred BALB C
Mice, Nude
NLR Family, Pyrin Domain-Containing 3 Protein
/ metabolism
BEAS-2B cells
NLRP3 inflammasome
coal tar pitch extract
lipopolysaccharide
malignant transformation
Journal
Environmental toxicology
ISSN: 1522-7278
Titre abrégé: Environ Toxicol
Pays: United States
ID NLM: 100885357
Informations de publication
Date de publication:
May 2019
May 2019
Historique:
received:
18
09
2018
revised:
06
01
2019
accepted:
14
01
2019
pubmed:
31
1
2019
medline:
21
5
2019
entrez:
31
1
2019
Statut:
ppublish
Résumé
Inflammatory microenvironment has been found as a new characteristic of cancer; however, the mechanisms of inflammation-related lung cancer remain unclear. To explore the role of NLRP3 inflammsome activation in inflammation-related lung carcinogenesis, a cell model was set up. Human bronchial epithelial cells (BEAS-2B) were stimulated with 1 μg/mL lipopolysaccharide (LPS) for 24 hours, and then treated with 2.4 μg/mL coal tar pitch extract (CTPE) for 24 hours, after removal of LPS and CTPE, the cells were numbered passage 1 and were passaged and treated in this way until passage 30, which was called LPS + CTPE group. DMSO and Saline were used as vehicle controls. Malignant transformation of cells in passage 30 was evaluated by morphological change, platelet clone formation assay, and tumor formation in nude mice. The mRNA levels of NLRP3 and IL-1β were detected by real time-PCR. The combination of NLRP3 and caspase-1 were determined using immunofluorescence and confocal. The protein expression of NLRP3, cleaved caspase-1(p10), and cleaved IL-1β was detected using Western blot. It was shown that CTPE, LPS + CTPE-stimulated BEAS-2B cells of passage 30 changed a lot morphologically. The clone formation rates, the rates of positive cells of NLRP3 and caspase-1 combination, the mRNA levels of NLRP3 and IL-1β, the protein expression of NLRP3, cleaved caspase-1(p10) and cleaved IL-1β of cells exposed with CTPE and LPS + CTPE at passage 30 were significantly increased compared to vehicle controls. Furthermore, the ability of tumor formation in nude mice, the rates of clone formation and positive cells, mRNA and protein levels of NLRP3 inflammasome activation-related factors in LPS + CTPE-induced cells were all higher than those in cells stimulated with CTPE alone. In conclusion, the cell model of inflammation-related lung cancer is set up successfully, and NLRP3 inflammasome activation may be involved in the malignant transformation of BEAS-2B cells which induced by CTPE alone or LPS combined with CTPE.
Substances chimiques
Inflammasomes
0
Interleukin-1beta
0
Lipopolysaccharides
0
NLR Family, Pyrin Domain-Containing 3 Protein
0
NLRP3 protein, human
0
Nlrp3 protein, mouse
0
Coal Tar
8007-45-2
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
585-593Subventions
Organisme : grant from Henan Department of Education
ID : 14A330001
Organisme : grants from Henan Department of Science and Technology, China
ID : 162102310319
Organisme : grants from Henan Department of Science and Technology, China
ID : 162102310602
Organisme : outstanding youth grant of Zhengzhou University
ID : 1421329082
Organisme : training grant of Zhengzhou University
ID : 2017ZDGGJS039
Organisme : Henan Department of Science and Technology, China
ID : 162102310602
Organisme : Henan Department of Science and Technology, China
ID : 162102310319
Organisme : Henan Department of Education
ID : 14A330001
Organisme : Zhengzhou University
ID : 2017ZDGGJS039
Organisme : Zhengzhou University
ID : 1421329082
Organisme : National Natural Science Foundation of China
ID : 81402712
Informations de copyright
© 2019 Wiley Periodicals, Inc.